Chen Zhuoyi, Niu Lingling, Zhao Jing, Yao Peijun, Wang Xiaoying, Zhou Xingtao
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
NHC Key Laboratory of Myopia (Fudan University), Shanghai, China.
Front Med (Lausanne). 2022 Feb 14;9:790137. doi: 10.3389/fmed.2022.790137. eCollection 2022.
To investigate the feasibility and safety of the implantable collamer lens V4c (ICL V4c) implantation without using an ophthalmic viscosurgical device (OVD-free technique).
This prospective consecutive case study enrolled 118 eyes of 60 patients (15 eyes were of male patients, 103 eyes were of female patients, age 26.19 ± 5.03 years, spherical equivalent -10.05 ± 2.73 D). Eyes were considered for OVD-free or OVD-using ICL V4c implantation based on the maintenance of the anterior segment during the surgery. The follow-up lasted for 12 months. The main measurements were visual acuity and changes in endothelial cell density (ECD) at 12 months.
A total of 75 eyes were included in the OVD-free group and 43 in the OVD group. No infection or other complications were observed in any eye. In the OVD-free group, the safety and efficacy indices were 1.19 ± 0.15 and 1.05 ± 0.20, respectively. 74.5% of the eyes gained one or two lines of corrected distance visual acuity (CDVA), and 25.5% were stable. In the OVD group, the safety and efficacy indices were 1.17 ± 0.17 and 1.03 ± 0.15, respectively; 65.7% of the eyes gained one or two lines of CDVA, and 34.3% were stable. The mean change of ECD was 65.34 cell/ mm compared to the baseline in the OVD-free group and 25.94 cell/ mm compared to baseline in the OVD group ( = 0.038).
The ICL V4c implantation with an OVD-free technique is a safe and feasible method in eyes with good maintenance of the anterior segment.
探讨不使用眼科粘弹剂（无粘弹剂技术）植入可植入式胶原晶状体V4c（ICL V4c）的可行性和安全性。
本前瞻性连续病例研究纳入了60例患者的118只眼（男性患者15只眼，女性患者103只眼，年龄26.19±5.03岁，等效球镜度数-10.05±2.73 D）。根据手术过程中前段的维持情况，考虑对眼睛进行无粘弹剂或使用粘弹剂的ICL V4c植入。随访持续12个月。主要测量指标为12个月时的视力和内皮细胞密度（ECD）变化。
无粘弹剂组共纳入75只眼，粘弹剂组纳入43只眼。所有眼中均未观察到感染或其他并发症。在无粘弹剂组中，安全性和有效性指数分别为1.19±0.15和1.05±0.20。74.5%的眼睛矫正远视力（CDVA）提高了一行或两行，25.5%保持稳定。在粘弹剂组中，安全性和有效性指数分别为1.17±0.17和1.03±0.15；65.7%的眼睛CDVA提高了一行或两行，34.3%保持稳定。与基线相比，无粘弹剂组ECD的平均变化为65.34个细胞/mm²，粘弹剂组为25.94个细胞/mm²（P = 0.038）。
对于前段维持良好的眼睛，采用无粘弹剂技术植入ICL V4c是一种安全可行的方法。
